Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.57 |
| ▸ | DHODH | Q02127 | 1/20 | 0.56 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21856899 | 0.88 | ACLY (0.65) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL30268534 | 0.88 | ACLY (0.65) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL21857246 | 0.88 | ACLY (0.65) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL2270222 | 0.84 | DHODH (0.77) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL28646206 | 0.83 | HDAC1 (0.47) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL2273186 | 0.82 | ACLY (0.68) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL2275453 | 0.82 | ACLY (0.76) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL2272605 | 0.80 | DHODH (0.73) | ACLYHDAC1HDAC2HDAC3DHODH | |
| SCHEMBL1320352 | 0.79 | ACMSD (0.68) | ACLYHDAC1HDAC2DHODH | |
| SCHEMBL2275720 | 0.79 | SUCNR1 (0.73) | ACLYHDAC1HDAC2HDAC3DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | ACLY 61/4885HDAC1 826/4885HDAC2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.